ADVANCED EPIDEMIC KAPOSI'S SARCOMA: TREATMENT WITH BLEOMYCIN OR COMBINATION OF DOXORUBICIN, BLEOMYCIN, AND VINCRISTINE
Article first published online: 31 MAY 2007
International Journal of Dermatology
Volume 35, Issue 11, pages 831–833, November 1996
How to Cite
HERNÁNDEZ, D. E. and PÉREZ, J. R. (1996), ADVANCED EPIDEMIC KAPOSI'S SARCOMA: TREATMENT WITH BLEOMYCIN OR COMBINATION OF DOXORUBICIN, BLEOMYCIN, AND VINCRISTINE. International Journal of Dermatology, 35: 831–833. doi: 10.1111/j.1365-4362.1996.tb02990.x
- Issue published online: 31 MAY 2007
- Article first published online: 31 MAY 2007
Background. Systemic chemotherapy is a treatment modality in the management of epidemic Kaposi's sarcoma (EKS). We conducted a prospective trial to compare bleomycin as a single agent with a regimen of low-dose doxorubicin, bleomycin, and vincristine (ABV) in patients with advanced EKS.
Methods. Twenty-four homosexual or bisexual patients, between 21 and 40 years old, with positive enzyme-linked Immunosorbent assay (ELISA) test for HIV and extensive EKS were included in the study. Half of the patients received bleomycin alone and the other half ABV.
Results. A total of seven patients achieved stable disease (SD) and five progressed during bleomycin treatment. A total of four patients achieved partial remission and eight SD during ABV treatment. There was no survival benefit between either arm of treatment.
Conclusions. Bleomycin alone is not a good starting agent for EKS, whereas ABV seems to be a good choice, because it can produce an acceptable palliation of advanced EKS without major toxicity.